Cytosponge™ Feasibility Study in Tanzania

NACompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

December 20, 2019

Study Completion Date

December 30, 2020

Conditions
Esophageal DiseasesEsophagus SCC
Interventions
DEVICE

Cytosponge™

The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.

Trial Locations (1)

Unknown

Majengo Unit, Kilimanjaro Clinical Research Institute, Moshi

All Listed Sponsors
collaborator

Kilimanjaro Clinical Research Institute

OTHER

collaborator

University of Cambridge

OTHER

lead

International Agency for Research on Cancer

OTHER